A preliminary injunction preventing the marketing and sale of Aegis Spine’s AccelFix-XT line of expandable medical devices is now in effect.
A U.S. District Court issued the injunction after finding that Aegis and its parent company, L&K Biomed, used Life Spine’s proprietary ProLift® expandable cage to develop the AccelFix-XT product line. As the Court explained, Aegis used its access to ProLift as Life Spine’s distributor to “discover the underlying specifications of the ProLift and then shared that information with surgeon consultants and L&K to reverse engineer the ProLift.”
The Court found that Life Spine is likely to succeed at trial in proving several of its claims, including breach of contract, breach of fiduciary duty and misappropriation of trade secrets. The injunction applies to Aegis and all those in active concert or participation with Aegis.
Life Spine’s CEO Michael Butler said, “We appreciate the Court’s thorough analysis of the issues and we are gratified that the Court’s order protects the years of hard work spent developing our ProLift series of products.”